187 related articles for article (PubMed ID: 9288183)
1. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
Dorai T; Olsson CA; Katz AE; Buttyan R
Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
[TBL] [Abstract][Full Text] [Related]
2. A recombinant defective adenoviral agent expressing anti-bcl-2 ribozyme promotes apoptosis of bcl-2-expressing human prostate cancer cells.
Dorai T; Perlman H; Walsh K; Shabsigh A; Goluboff ET; Olsson CA; Buttyan R
Int J Cancer; 1999 Sep; 82(6):846-52. PubMed ID: 10446452
[TBL] [Abstract][Full Text] [Related]
3. Development of a hammerhead ribozyme against BCL-2. II. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents.
Dorai T; Goluboff ET; Olsson CA; Buttyan R
Anticancer Res; 1997; 17(5A):3307-12. PubMed ID: 9413164
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of bcl-2 expression in lymphoma cells by bcl-2 ARE-targeted modified, synthetic ribozyme.
Luzi E; Papucci L; Schiavone N; Donnini M; Lapucci A; Tempestini A; Witort E; Nicolin A; Capaccioli S
Cancer Gene Ther; 2003 Mar; 10(3):201-8. PubMed ID: 12637941
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo.
Raffo AJ; Perlman H; Chen MW; Day ML; Streitman JS; Buttyan R
Cancer Res; 1995 Oct; 55(19):4438-45. PubMed ID: 7671257
[TBL] [Abstract][Full Text] [Related]
6. Hammerhead ribozyme targeting connective tissue growth factor mRNA blocks transforming growth factor-beta mediated cell proliferation.
Blalock TD; Yuan R; Lewin AS; Schultz GS
Exp Eye Res; 2004 Jun; 78(6):1127-36. PubMed ID: 15109919
[TBL] [Abstract][Full Text] [Related]
7. Selection of a high activity c-erbB-2 ribozyme using a fusion gene of c-erbB-2 and the enhanced green fluorescent protein.
Wiechen K; Zimmer C; Dietel M
Cancer Gene Ther; 1998; 5(1):45-51. PubMed ID: 9476966
[TBL] [Abstract][Full Text] [Related]
8. Induction of apoptosis in oral cancer cells by an anti-bcl-2 ribozyme delivered by an adenovirus vector.
Gibson SA; Pellenz C; Hutchison RE; Davey FR; Shillitoe EJ
Clin Cancer Res; 2000 Jan; 6(1):213-22. PubMed ID: 10656452
[TBL] [Abstract][Full Text] [Related]
9. Ribozyme-mediated downregulation of human metallothionein II(a) induces apoptosis in human prostate and ovarian cancer cell lines.
Tekur S; Ho SM
Mol Carcinog; 2002 Jan; 33(1):44-55. PubMed ID: 11807957
[TBL] [Abstract][Full Text] [Related]
10. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes.
Mercatanti A; Rainaldi G; Mariani L; Marangoni R; Citti L
J Comput Biol; 2002; 9(4):641-53. PubMed ID: 12323098
[TBL] [Abstract][Full Text] [Related]
11. In vitro catalytic activities of DNA/RNA chimeric hammerhead ribozymes against AML1-MTG8 mRNA, a fused gene transcript in acute myeloid leukemia with t(8;21).
Kozu T; Sueoka E; Okabe S; Sueoka N; Komori A; Fujiki H
Biochimie; 1996; 78(11-12):1067-73. PubMed ID: 9150886
[TBL] [Abstract][Full Text] [Related]
12. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
Hayashidani Y; Hiyama E; Murakami Y; Sueda T
Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
[TBL] [Abstract][Full Text] [Related]
13. miR-143 Induces the Apoptosis of Prostate Cancer LNCap Cells by Suppressing Bcl-2 Expression.
Ma Z; Luo Y; Qiu M
Med Sci Monit; 2017 Jan; 23():359-365. PubMed ID: 28109198
[TBL] [Abstract][Full Text] [Related]
14. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
Phylactou LA; Tsipouras P; Kilpatrick MW
Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
[TBL] [Abstract][Full Text] [Related]
15. Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme.
Yokoyama Y; Morishita S; Takahashi Y; Hashimoto M; Tamaya T
Br J Cancer; 1997; 76(8):977-82. PubMed ID: 9376277
[TBL] [Abstract][Full Text] [Related]
16. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
[TBL] [Abstract][Full Text] [Related]
17. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
[TBL] [Abstract][Full Text] [Related]
18. Characterization of pro-apoptotic gene Bak using hammerhead ribozymes.
Suyama E; Kawasaki H; Taira K
Nucleic Acids Res Suppl; 2001; (1):207-8. PubMed ID: 12836337
[TBL] [Abstract][Full Text] [Related]
19. Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells.
Xu ZD; Oey L; Mohan S; Kawachi MH; Lee NS; Rossi JJ; Fujita-Yamaguchi Y
Endocrinology; 1999 May; 140(5):2134-44. PubMed ID: 10218964
[TBL] [Abstract][Full Text] [Related]
20. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
